Establishment of Integration-Free Human Induced Pluripotent Stem Cells from A Patient with Primary Myelofibrosis.
- Author:
Jing XU
1
;
Meng-Yao SHENG
2
;
Yuan ZHOU
2
;
Wen XING
2
;
Jie BAI
2
;
Wei WEN
2
;
Guang-Zhen JI
2
;
Hong-Yan ZHANG
2
;
Hui JIN
2
;
Cui-Cui LYU
2
;
Wei-Ping YUAN
2
;
Xiao-Bing ZHANG
2
;
Tao CHENG
2
Author Information
- Publication Type:Journal Article
- MeSH: Alleles; Animals; Cell Culture Techniques; Humans; Induced Pluripotent Stem Cells; Janus Kinase 2; genetics; Mice; Mice, Inbred NOD; Mice, SCID; Mutation; Primary Myelofibrosis
- From: Journal of Experimental Hematology 2015;23(5):1415-1421
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo establish the primary myelofibrosis (PMF)-induced pluripotent stem cell line (iPSC) by means of iPSC techinique so as to provide a experimental model for studying the blood disease mechanisms.
METHODSInduced pluripotent stem cells were generated from mononuclear cells isolated from a PMF patient with JAK2(V617F) mutation by using episomal vectors.
RESULTSPMF-derived iPSC was established from the patient with JAK2(V617F) gene mutation. The PMF-iPSC could be stably passaged, highly expressed pluripotent genes as human embryonic stem (ES) cells, and were able to form teratoma in NOD/SCID mice in vivo. H & E staining of the teratoma showed the presence of tissue type derived from all three embryonic germ layers. Sanger sequencing confirmed that PMF-derived iPSC carried different allele burdens of JAK2(V617F) gene mutation.
CONCLUSIONThe interation-free iPSC from primary myelofibrosis patient in vitro has been established. This PMF-derived iPSC line provides a valuable tool for studying the pathogenesis, screening of chimical drugs and realizing the standard therapy of PMF.
